3 results
Approved WMOCompleted
To determine appropriate dosing regimens for use in future clinical trials of GS 9820 in subjects with lymphoid malignancies.
Approved WMOCompleted
Part 1: The primary objective is to investigate if the RNFL-ac in PD patients differs significantly from the RNFL-ac in healthy controls.Secondary Objectives are:1) to investigate if the RNFL-ac can be used to differentiate PD patients from healthy…
Not approvedWill not start
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…